Download PDF
Semin Thromb Hemost 2008; 34(2): 187-194
DOI: 10.1055/s-2008-1079259
© Thieme Medical Publishers

Heparanase, Tissue Factor, and Cancer

Yona Nadir1 , Israel Vlodavsky2 , Benjamin Brenner1
  • 1Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Medical Center, Haifa, Israel
  • 2Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Further Information

Publication History

Publication Date:
21 July 2008 (online)

    Permissions and Reprints

ABSTRACT

Heparanase is an endo-β-D-glucuronidase that is capable of cleaving heparan sulfate side chains of heparan sulfate proteoglycans on cell surfaces and the extracellular matrix, activity that is strongly implicated in tumor metastasis and angiogenesis. Evidence was provided that heparanase overexpression in human leukemia, glioma, and breast carcinoma cells results in a marked increase in tissue factor (TF) levels. Likewise, TF was induced by exogenous addition of recombinant heparanase to tumor cells and primary endothelial cells, induction that was mediated by p38 phosphorylation and correlated with enhanced procoagulant activity. TF induction was further confirmed in heparanase-overexpressing transgenic mice and correlated with heparanase expression levels in leukemia patients. Heparanase was also found to be involved in the regulation of tissue factor pathway inhibitor (TFPI). It was shown that heparanase overexpression or exogenous addition induces two- to threefold increase of TFPI expression. Similarly, heparanase stimulated accumulation of TFPI in the cell culture medium. Extracellular accumulation exceeded, however, the observed increase in TFPI at the protein level and appeared to be independent of heparan sulfate and heparanase enzymatic activity. Instead, a physical interaction between heparanase and TFPI was demonstrated, suggesting a mechanism by which secreted heparanase interacts with TFPI on the cell surface, leading to dissociation of TFPI from the cell membrane and increased coagulation activity, thus further supporting the local prothrombotic function of heparanase. As heparins are strong inhibitors of heparanase, in view of the effect of heparanase on TF/TFPI pathway, the role of heparins' anticoagulant activity may potentially be expanded.

KEYWORDS

Heparanase - tissue factor - tissue factor pathway inhibitor - cancer

REFERENCES

  • 1 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms.  Crit Rev Oncol Hematol. 2004;  50 187-196
    PubMedGoogle Scholar
  • 2 Haim N, Lanir N, Hoffman R et al.. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.  Am J Med. 2001;  110 91-96
    CrossrefPubMedGoogle Scholar
  • 3 Rao L V, Pendurthi U R. Tissue factor-factor VIIa signaling.  Arterioscler Thromb Vasc Biol. 2005;  25 47-56
    PubMedGoogle Scholar
  • 4 Versteeg H H, Ruf W. Emerging insights in tissue factor-dependent signaling events.  Semin Thromb Hemost. 2006;  32 24-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects.  Arterioscler Thromb Vasc Biol. 2002;  22 539-548
    CrossrefPubMedGoogle Scholar
  • 6 Lwaleed B A, Bass P S. Tissue factor pathway inhibitor: structure, biology and involvement in disease.  J Pathol. 2006;  208 327-339
    PubMedGoogle Scholar
  • 7 Freeman C, Parish C R. Human platelet heparanase: purification, characterization and catalytic activity.  Biochem J. 1998;  330 1341-1350
    PubMedGoogle Scholar
  • 8 Pikas D S, Li J P, Vlodavsky I et al.. Substrate specificity of heparanases from human hepatoma and platelets.  J Biol Chem. 1998;  273 18770-18777
    CrossrefPubMedGoogle Scholar
  • 9 Parish C R, Freeman C, Hulett M D. Heparanase: a key enzyme involved in cell invasion.  Biochim Biophys Acta. 2001;  1471 M99-M108
    PubMedGoogle Scholar
  • 10 Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.  J Clin Invest. 2001;  108 341-347
    CrossrefPubMedGoogle Scholar
  • 11 Dempsey L A, Brunn G J, Platt J L. Heparanase, a potential regulator of cell-matrix interactions.  Trends Biochem Sci. 2000;  25 349-351
    CrossrefPubMedGoogle Scholar
  • 12 Hulett M D, Freeman C, Hamdorf B J et al.. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.  Nat Med. 1999;  5 803-809
    PubMedGoogle Scholar
  • 13 Kussie P H, Hulmes J D, Ludwig D L et al.. Cloning and functional expression of a human heparanase gene.  Biochem Biophys Res Commun. 1999;  261 183-187
    CrossrefPubMedGoogle Scholar
  • 14 Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression.  J Biol Chem. 1999;  274 24153-24160
    CrossrefPubMedGoogle Scholar
  • 15 Vlodavsky I, Friedmann Y, Elkin M et al.. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis.  Nat Med. 1999;  5 793-802
    PubMedGoogle Scholar
  • 16 Goldshmidt O, Zcharia E, Aingorn H et al.. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence.  J Biol Chem. 2001;  276 29178-29187
    CrossrefPubMedGoogle Scholar
  • 17 Elkin M, Ilan N, Ishai-Michaeli R et al.. Heparanase as mediator of angiogenesis: mode of action.  FASEB J. 2001;  15 1661-1663
    PubMedGoogle Scholar
  • 18 Friedmann Y, Vlodavsky I, Aingorn H et al.. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.  Am J Pathol. 2000;  157 1167-1175
    PubMedGoogle Scholar
  • 19 Folkman J, Klagsbrun M, Sasse J et al.. A heparin-binding angiogenic protein–basic fibroblast growth factor–is stored within basement membrane.  Am J Pathol. 1988;  130 393-400
    PubMedGoogle Scholar
  • 20 Vlodavsky I, Miao H Q, Medalion B et al.. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.  Cancer Metastasis Rev. 1996;  15 177-186
    CrossrefPubMedGoogle Scholar
  • 21 Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R et al.. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?.  Trends Biochem Sci. 1991;  16 268-271
    CrossrefPubMedGoogle Scholar
  • 22 Sato T, Yamaguchi A, Goi T et al.. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis.  J Surg Oncol. 2004;  87 174-181
    CrossrefPubMedGoogle Scholar
  • 23 Xu X, Quiros R M, Maxhimer J B et al.. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.  Clin Cancer Res. 2003;  9 5968-5979
    PubMedGoogle Scholar
  • 24 El-Assal O N, Yamanoi A, Ono T et al.. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma.  Clin Cancer Res. 2001;  7 1299-1305
    PubMedGoogle Scholar
  • 25 Kim A W, Xu X, Hollinger E F et al.. Human heparanase-1 gene expression in pancreatic adenocarcinoma.  J Gastrointest Surg. 2002;  6 167-172
    CrossrefPubMedGoogle Scholar
  • 26 Rohloff J, Zinke J, Schoppmeyer K et al.. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma.  Br J Cancer. 2002;  86 1270-1275
    CrossrefPubMedGoogle Scholar
  • 27 Gohji K, Okamoto M, Kitazawa S et al.. Heparanase protein and gene expression in bladder cancer.  J Urol. 2001;  166 1286-1290
    CrossrefPubMedGoogle Scholar
  • 28 Gohji K, Hirano H, Okamoto M et al.. Expression of three extracellular matrix degradative enzymes in bladder cancer.  Int J Cancer. 2001;  95 295-301
    CrossrefPubMedGoogle Scholar
  • 29 Shinyo Y, Kodama J, Hongo A et al.. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer.  Ann Oncol. 2003;  14 1505-1510
    CrossrefPubMedGoogle Scholar
  • 30 Maxhimer J B, Quiros R M, Stewart R et al.. Heparanase-1 expression is associated with the metastatic potential of breast cancer.  Surgery. 2002;  132 326-333
    CrossrefPubMedGoogle Scholar
  • 31 Takaoka M, Naomoto Y, Ohkawa T et al.. Heparanase expression correlates with invasion and poor prognosis in gastric cancers.  Lab Invest. 2003;  83 613-622
    PubMedGoogle Scholar
  • 32 Tang W, Nakamura Y, Tsujimoto M et al.. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma.  Mod Pathol. 2002;  15 593-598
    CrossrefPubMedGoogle Scholar
  • 33 Ogishima T, Shiina H, Breault J E et al.. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.  Clin Cancer Res. 2005;  11 1028-1036
    PubMedGoogle Scholar
  • 34 Beckhove P, Helmke B M, Ziouta Y et al.. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis.  Clin Cancer Res. 2005;  11 2899-2906
    CrossrefPubMedGoogle Scholar
  • 35 Mikami S, Ohashi K, Usui Y et al.. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.  Jpn J Cancer Res. 2001;  92 1062-1073
    PubMedGoogle Scholar
  • 36 Kelly T, Miao H Q, Yang Y et al.. High heparanase activity in multiple myeloma is associated with elevated microvessel density.  Cancer Res. 2003;  63 8749-8756
    PubMedGoogle Scholar
  • 37 Bitan M, Polliack A, Zecchina G et al.. Heparanase expression in human leukemias is restricted to acute myeloid leukemias.  Exp Hematol. 2002;  30 34-41
    CrossrefPubMedGoogle Scholar
  • 38 Schubert S Y, Ilan N, Shushy M et al.. Human heparanase nuclear localization and enzymatic activity.  Lab Invest. 2004;  84 535-544
    CrossrefPubMedGoogle Scholar
  • 39 Ohkawa T, Naomoto Y, Takaoka M et al.. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation.  Lab Invest. 2004;  84 1289-1304
    CrossrefPubMedGoogle Scholar
  • 40 Doweck I, Kaplan-Cohen V, Naroditsky I et al.. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.  Neoplasia. 2006;  8 1055-1061
    CrossrefPubMedGoogle Scholar
  • 41 Goldshmidt O, Zcharia E, Cohen M et al.. Heparanase mediates cell adhesion independent of its enzymatic activity.  FASEB J. 2003;  17 1015-1025
    CrossrefPubMedGoogle Scholar
  • 42 Gingis-Velitski S, Zetser A, Flugelman M Y et al.. Heparanase induces endothelial cell migration via protein kinase B/Akt activation.  J Biol Chem. 2004;  279 23536-23541
    CrossrefPubMedGoogle Scholar
  • 43 Zetser A, Bashenko Y, Edovitsky E et al.. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.  Cancer Res. 2006;  66 1455-1463
    CrossrefPubMedGoogle Scholar
  • 44 Vlodavsky I, Eldor A, Haimovitz-Friedman A et al.. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.  Invasion Metastasis. 1992;  12 112-127
    PubMedGoogle Scholar
  • 45 Yang Y, MacLeod V, Dai Y et al.. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.  Blood. 2007;  110 2041-2048
    CrossrefPubMedGoogle Scholar
  • 46 Labarrere C A, Pitts D, Halbrook H et al.. Natural anticoagulant pathways in normal and transplanted human hearts.  J Heart Lung Transplant. 1992;  11 342-347
    PubMedGoogle Scholar
  • 47 de Agostini A I, Watkins S C, Slayter H S et al.. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta.  J Cell Biol. 1990;  111 1293-1304
    CrossrefPubMedGoogle Scholar
  • 48 Girardin E P, Hajmohammadi S, Birmele B et al.. Synthesis of anticoagulantly active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool.  J Biol Chem. 2005;  280 38059-38070
    CrossrefPubMedGoogle Scholar
  • 49 Sarafanov A G, Ananyeva N M, Shima M et al.. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein.  J Biol Chem. 2001;  276 11970-11979
    CrossrefPubMedGoogle Scholar
  • 50 Ho G, Broze Jr G J, Schwartz A L. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes.  J Biol Chem. 1997;  272 16838-16844
    CrossrefPubMedGoogle Scholar
  • 51 Iozzo R V. Basement membrane proteoglycans: from cellar to ceiling.  Nat Rev. 2005;  6 646-656
    CrossrefPubMedGoogle Scholar
  • 52 Parish C R, Coombe D R, Jakobsen K B et al.. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases.  Int J Cancer. 1987;  40 511-518
    PubMedGoogle Scholar
  • 53 Bar-Ner M, Eldor A, Wasserman L et al.. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.  Blood. 1987;  70 551-557
    CrossrefPubMedGoogle Scholar
  • 54 Naggi A, Casu B, Perez M et al.. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.  J Biol Chem. 2005;  280 12103-12113
    CrossrefPubMedGoogle Scholar
  • 55 Katz B Z, Muhl L, Zwang E et al.. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.  Thromb Haemost. 2007;  98 1193-1199
    PubMedGoogle Scholar
  • 56 Nadir Y, Brenner B, Zetser A et al.. Heparanase induces tissue factor expression in vascular endothelial and cancer cells.  J Thromb Haemost. 2006;  4 2443-2451
    CrossrefPubMedGoogle Scholar
  • 57 Vreys V, Delande N, Zhang Z et al.. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans.  J Biol Chem. 2005;  280 33141-33148
    CrossrefPubMedGoogle Scholar
  • 58 Zetser A, Bashenko Y, Miao H Q et al.. Heparanase affects adhesive and tumorigenic potential of human glioma cells.  Cancer Res. 2003;  63 7733-7741
    PubMedGoogle Scholar
  • 59 Sotnikov I, Hershkoviz R, Grabovsky V et al.. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts.  J Immunol. 2004;  172 5185-5193
    CrossrefPubMedGoogle Scholar
  • 60 Bashkin P, Doctrow S, Klagsbrun M et al.. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.  Biochemistry. 1989;  28 1737-1743
    CrossrefPubMedGoogle Scholar
  • 61 Lopez-Pedrera C, Buendia P, Cuadrado M J et al.. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway.  Arthritis Rheum. 2006;  54 301-311
    CrossrefPubMedGoogle Scholar
  • 62 Ohsawa M, Koyama T, Nara N et al.. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38.  Thromb Res. 2003;  112 313-320
    CrossrefPubMedGoogle Scholar
  • 63 Zcharia E, Metzger S, Chajek-Shaul T et al.. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior.  FASEB J. 2004;  18 252-263
    CrossrefPubMedGoogle Scholar
  • 64 Nadir Y, Brenner B, Gingis-Velitski S et al.. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.  Thromb Haemost. 2008;  99 133-141
    PubMedGoogle Scholar
  • 65 Iversen N, Lindahl A K, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation.  Br J Haematol. 1998;  102 889-895
    CrossrefPubMedGoogle Scholar
  • 66 Iversen N, Lindahl A K, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients.  Thromb Res. 2002;  105 33-36
    CrossrefPubMedGoogle Scholar
  • 67 Shafat I, Zcharia E, Nisman B et al.. An ELISA method for the detection and quantification of human heparanase.  Biochem Biophys Res Commun. 2006;  341 958-963
    CrossrefPubMedGoogle Scholar
  • 68 Gingis-Velitski S, Zetser A, Kaplan V et al.. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans.  J Biol Chem. 2004;  279 44084-44092
    CrossrefPubMedGoogle Scholar
  • 69 Vlodavsky I, Abboud-Jarrous G, Elkin M et al.. The impact of heparanese and heparin on cancer metastasis and angiogenesis.  Pathophysiol Haemost Thromb. 2006;  35 116-127
    CrossrefPubMedGoogle Scholar
  • 70 Bar-Sela G, Kaplan-Cohen V, Ilan N et al.. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival.  Histopathology. 2006;  49 188-193
    CrossrefPubMedGoogle Scholar

Yona NadirM.D. Ph.D. 

Thrombosis and Hemostasis Unit, Department of Hematology

Rambam Medical Center, Haifa, Israel

Email: ynadir@netvision.net.il